# Atezolizumab Plus Induction Chemotherapy Plus CT-radiotherapy. (APOLO)

> **NCT04776447** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Fundación GECP** · enrollment: 38 (actual)

## Conditions studied

- Lung Diseases
- Carcinoma, Non-Small-Cell Lung
- Stage IIIA Non-small Cell Lung Cancer
- Stage IIIB Non-small Cell Lung Cancer
- Respiratory Tract Neoplasms
- Carcinoma Bronchiogenic Stage III
- Thoracic Neoplasms

## Interventions

- **DRUG:** Carboplatin
- **DRUG:** Placlitaxel
- **DRUG:** Atezolizumab

## Key facts

- **NCT ID:** NCT04776447
- **Lead sponsor:** Fundación GECP
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2021-06-16
- **Primary completion:** 2026-11-15
- **Final completion:** 2027-11-15
- **Target enrollment:** 38 (ACTUAL)
- **Last updated:** 2025-04-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04776447

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04776447, "Atezolizumab Plus Induction Chemotherapy Plus CT-radiotherapy. (APOLO)". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT04776447. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*